Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Management of pegvaliase-related skin concerns: best practice recommendations using a modified Delphi approach.

Molecular genetics and metabolism·2026
Same author

Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study.

Journal of psychopharmacology (Oxford, England)·2025
Same author

Testing the efficacy of surface swab sampling to determine postmortem submersion interval (PMSI), using the microbiome colonization of skeletal remains.

Journal of forensic sciences·2025
Same journal

Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Reply to Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.

Maria Papathanou1, Rika van der Laan, Peter Jenner

  • 1Abbott Healthcare Products B.V., Weesp, the Netherlands.

Movement Disorders : Official Journal of the Movement Disorder Society
|November 6, 2012
PubMed
Summary
This summary is machine-generated.

Continuous levodopa (l-dopa) delivery via intraduodenal infusion did not prevent dyskinesia in rats. However, continuous delivery reduced the duration of established involuntary movements, aligning with clinical findings.

Keywords:
6-OHDA-lesioned ratsAIMsParkinson's diseasedyskinesiaintraduodenal levodopa infusion

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: May 17, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • Pulsatile levodopa (l-dopa) stimulation of dopamine receptors contributes to motor fluctuations and dyskinesia in Parkinson's disease.
  • Novel delivery systems, including intraduodenal (i.d.) infusions and controlled-release formulations, aim to provide more continuous l-dopa delivery.
  • Understanding the impact of different l-dopa administration methods on dyskinesia induction and expression is crucial for optimizing treatment.

Purpose of the Study:

  • To compare the effects of pulsatile intraperitoneal (i.p.) administration versus continuous i.d. infusion of l-dopa on the induction and expression of abnormal involuntary movements (AIMs).
  • To investigate whether continuous l-dopa delivery can prevent or reduce dyskinesia in a 6-hydroxydopamine (6-OHDA) rat model.

Main Methods:

  • 6-OHDA-lesioned rats received either twice-daily i.p. l-dopa/carbidopa or an 8-hour daily i.d. infusion of l-dopa/carbidopa for 14 days.
  • Treatments were switched between groups for a subsequent 14-day period.
  • Abnormal involuntary movements (AIMs) severity and duration were assessed throughout the study.

Main Results:

  • Pulsatile i.p. l-dopa administration induced moderate to severe AIMs, which progressively worsened.
  • Continuous i.d. l-dopa infusion induced AIMs of similar severity to pulsatile administration, indicating it did not prevent dyskinesia induction.
  • Switching from i.d. to i.p. administration maintained severe AIMs, while switching from i.p. to i.d. administration did not alter peak AIM severity but reduced their duration.

Conclusions:

  • Less pulsatile levodopa administration via intraduodenal infusion does not reduce the risk of developing dyskinesia.
  • Continuous levodopa delivery, as achieved by i.d. infusion, can reduce the duration of established dyskinesia.
  • These findings support the clinical observation that continuous l-dopa delivery may help manage established dyskinesia.